E Fund Management Co. Ltd. Sells 2,431 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

E Fund Management Co. Ltd. lowered its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 23.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,954 shares of the biopharmaceutical company’s stock after selling 2,431 shares during the period. E Fund Management Co. Ltd.’s holdings in Halozyme Therapeutics were worth $416,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Mutual of America Capital Management LLC raised its stake in shares of Halozyme Therapeutics by 31.1% in the second quarter. Mutual of America Capital Management LLC now owns 183,941 shares of the biopharmaceutical company’s stock valued at $9,631,000 after acquiring an additional 43,614 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Halozyme Therapeutics by 12.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock valued at $99,363,000 after acquiring an additional 209,530 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in shares of Halozyme Therapeutics by 4.9% in the second quarter. Envestnet Asset Management Inc. now owns 229,620 shares of the biopharmaceutical company’s stock valued at $12,023,000 after acquiring an additional 10,651 shares during the last quarter. O Neil Global Advisors Inc. bought a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $249,000. Finally, Federated Hermes Inc. raised its stake in shares of Halozyme Therapeutics by 37.8% in the second quarter. Federated Hermes Inc. now owns 696,131 shares of the biopharmaceutical company’s stock valued at $36,449,000 after acquiring an additional 191,030 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $62.31 on Thursday. Halozyme Therapeutics, Inc. has a 12-month low of $32.83 and a 12-month high of $65.53. The firm has a market capitalization of $7.93 billion, a price-to-earnings ratio of 25.75, a price-to-earnings-growth ratio of 0.57 and a beta of 1.28. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The firm has a fifty day moving average of $58.14 and a 200-day moving average of $48.95.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The company had revenue of $231.40 million during the quarter, compared to analyst estimates of $204.94 million. During the same quarter in the previous year, the business earned $0.68 EPS. The firm’s revenue was up 4.7% on a year-over-year basis. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 3.7 earnings per share for the current year.

Insider Activity

In other news, CFO Nicole Labrosse sold 10,000 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $51.93, for a total value of $519,300.00. Following the completion of the transaction, the chief financial officer now owns 15,480 shares of the company’s stock, valued at approximately $803,876.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Matthew L. Posard sold 9,881 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total value of $570,133.70. Following the sale, the director now directly owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Nicole Labrosse sold 10,000 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $51.93, for a total transaction of $519,300.00. Following the completion of the sale, the chief financial officer now directly owns 15,480 shares in the company, valued at $803,876.40. The disclosure for this sale can be found here. Insiders sold 84,881 shares of company stock valued at $4,888,184 in the last quarter. Company insiders own 2.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on HALO. Benchmark reissued a “buy” rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Morgan Stanley raised their price target on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Wells Fargo & Company raised their price target on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, June 7th. TD Cowen raised their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $65.00 price target on shares of Halozyme Therapeutics in a report on Friday, September 13th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $59.44.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.